Fiona Marra

692 total citations · 1 hit paper
27 papers, 413 citations indexed

About

Fiona Marra is a scholar working on Hepatology, Infectious Diseases and Rheumatology. According to data from OpenAlex, Fiona Marra has authored 27 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hepatology, 8 papers in Infectious Diseases and 7 papers in Rheumatology. Recurrent topics in Fiona Marra's work include Hepatitis C virus research (17 papers), HIV/AIDS drug development and treatment (7 papers) and Systemic Lupus Erythematosus Research (6 papers). Fiona Marra is often cited by papers focused on Hepatitis C virus research (17 papers), HIV/AIDS drug development and treatment (7 papers) and Systemic Lupus Erythematosus Research (6 papers). Fiona Marra collaborates with scholars based in United Kingdom, United States and Germany. Fiona Marra's co-authors include David Back, Saye Khoo, Alison Boyle, Catia Marzolini, Sara Gibbons, David M. Burger, Marta Boffito, Daniel R. Kuritzkes, Laura Waters and Charles Flexner and has published in prestigious journals such as Clinical Infectious Diseases, Journal of Hepatology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Fiona Marra

23 papers receiving 401 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

2022 162 citations Catia Marzolini, Daniel R. Kuritzkes et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fiona Marra United Kingdom	9	200	153	141	45	40	27	413
Elise J. Smolders Netherlands	13	185 0.9×	204 1.3×	234 1.7×	43 1.0×	61 1.5×	31	472
Annabelle Lemenuel‐Diot Switzerland	11	73 0.4×	74 0.5×	175 1.2×	33 0.7×	54 1.4×	24	487
Aurélie Barrail‐Tran France	16	387 1.9×	36 0.2×	112 0.8×	44 1.0×	75 1.9×	35	639
Fabian Franzeck Switzerland	12	159 0.8×	28 0.2×	117 0.8×	18 0.4×	46 1.1×	25	411
Cheri E. Klein United States	16	293 1.5×	95 0.6×	91 0.6×	106 2.4×	123 3.1×	34	930
Lauren M. Hynicka United States	10	105 0.5×	41 0.3×	114 0.8×	13 0.3×	44 1.1×	21	317
Orietta Staltari Italy	9	41 0.2×	96 0.6×	111 0.8×	34 0.8×	28 0.7×	17	304
Chantal Valiquette Canada	7	462 2.3×	58 0.4×	327 2.3×	215 4.8×	61 1.5×	12	742
Nancy L. Sheehan Canada	12	212 1.1×	21 0.1×	93 0.7×	114 2.5×	53 1.3×	34	518

Countries citing papers authored by Fiona Marra

Since Specialization

Citations

This map shows the geographic impact of Fiona Marra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fiona Marra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fiona Marra more than expected).

Fields of papers citing papers by Fiona Marra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fiona Marra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fiona Marra. The network helps show where Fiona Marra may publish in the future.

Co-authorship network of co-authors of Fiona Marra

This figure shows the co-authorship network connecting the top 25 collaborators of Fiona Marra. A scholar is included among the top collaborators of Fiona Marra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fiona Marra. Fiona Marra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marra, Fiona, et al.. (2023). P41 Biochemical response to bezafibrate amongst patients with PBC and ursodeoxycholic acid non-response. Poster presentations. A39.1–A39.

Hodge, Daryl, Eva Maria Hodel, Sara Gibbons, et al.. (2023). Prevalence of Potentially Clinically Significant Drug–Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature. JAIDS Journal of Acquired Immune Deficiency Syndromes. 92(2). 97–105. 5 indexed citations

Forsyth, Paul, Andrew Radley, Gordon F. Rushworth, et al.. (2022). The Collaborative Care Model: Realizing healthcare values and increasing responsiveness in the pharmacy workforce. Research in Social and Administrative Pharmacy. 19(1). 110–122. 16 indexed citations

Marzolini, Catia, Daniel R. Kuritzkes, Fiona Marra, et al.. (2022). Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clinical Pharmacology & Therapeutics. 112(6). 1191–1200. 162 indexed citations breakdown →

Boyle, Alison, et al.. (2022). Safe co‐administration of direct‐acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study. Journal of Viral Hepatitis. 29(12). 1073–1078. 3 indexed citations

Marra, Fiona, Elise J. Smolders, Omar El‐Sherif, et al.. (2020). Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. Drugs in R&D. 21(1). 9–27. 39 indexed citations

Lampertico, Pietro, Stefan Mauss, Marcello Persico, et al.. (2020). Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis. Advances in Therapy. 37(9). 4033–4042. 15 indexed citations

Davidson, Katherine, et al.. (2020). The quetiapine question: management strategies for drug-drug interactions with antipsychotics and direct acting antivirals; a multicentre review. Journal of Hepatology. 73. S349–S349.

Boyle, Alison, Fiona Marra, T. Ritchíe, et al.. (2019). Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. Journal of Viral Hepatitis. 27(4). 371–375. 4 indexed citations

10.

Ferenci, Péter, Stefan Bourgeois, Peter Buggisch, et al.. (2019). Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries. Journal of Viral Hepatitis. 26(6). 685–696. 9 indexed citations

11.

Back, David, Pamela S. Belperio, Francesco Negro, et al.. (2019). Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. Journal of Viral Hepatitis. 26(8). 951–960. 20 indexed citations

12.

Boyle, Alison, et al.. (2019). THU-130-Management strategies for drug drug interactions between direct oral anticoagulants and hepatitis C directly acting agents: A multicentre review. Journal of Hepatology. 70(1). e216–e217. 3 indexed citations

13.

Boyle, Alison, Fiona Marra, Rory Gunson, et al.. (2019). THU-121-Real world outcomes from NS5a treatment failures undergoing therapy with sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/ glecaprevir/pibrentasvir. Journal of Hepatology. 70(1). e212–e212.

14.

Marra, Fiona, Edgar J.G. Peters, Mathis Heydtmann, et al.. (2018). 8 weeks sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: Highly effective amongst an OST cohort. Journal of Hepatology. 68. S20–S20. 2 indexed citations

15.

Marra, Fiona, Christoph Höner zu Siederdissen, Saye Khoo, et al.. (2018). Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. British Journal of Clinical Pharmacology. 84(5). 961–971. 2 indexed citations

16.

Marra, Fiona, Ray Fox, Catherine Fleming, et al.. (2017). Successful management of drug interactions with ritonavir-containing hepatitis C virus regimens in routine clinical practice. Journal of Hepatology. 66(1). S314–S315. 1 indexed citations

17.

Thomson, Emma C., Shalini Datta, Raymond G. Fox, et al.. (2016). Efficacy of Sofosbuvir/Ledipasvir in Treating Genotype 1 and 4 Hepatitis C for 8/12 Weeks: Results from a Difficult to Treat Cohort. Journal of Hepatology. 64(2). S805–S805. 1 indexed citations

18.

Siederdissen, Christoph Höner zu, Benjamin Maasoumy, Fiona Marra, et al.. (2015). Drug–Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. Clinical Infectious Diseases. 62(5). 561–567. 77 indexed citations

19.

Christensen, Søren, Fiona Marra, & Karel Kostev. (2015). High Rates of Comorbidities and Polypharmacy in Patients with Chronic Hepatitis C in Germany: Results of a large cross-sectional study. Zeitschrift für Gastroenterologie. 53(8). 1 indexed citations

20.

Benedetto, Michele De, et al.. (2006). Extra-laryngeal manifestations of gastro-oesophageal reflux.. PubMed. 26(5). 256–9. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact